Absci Corporation ABSI
Promising (early) Emerging Frontier sector · Absci — generative-AI antibody drug design, early-stage and speculative.
🗓 Reports earnings in 86 days (2026-11-16) — calendar context, not a prediction.
Absci Corporation (ABSI) is an early-stage Emerging Frontier company, graded Promising (early) on FrontierLab's evidence-based quality rubric (data as of 2026-08-21). Gross-profits-to-assets is -0.01; Rule of 40 is -8473.6. Net share issuance 23.4% YoY (heavy issuance). 3 risk flags are noted below. Analyst mix: 14 buy / 2 hold / 0 sell. 1 distinct insider cluster-buyer in the last 90 days.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | -0.01 |
| Rule of 40 | -8473.6 |
| Net margin | -8411.3% |
| Cash runway (months) | 22.3 |
| PEG | — |
| Price / sales | 1007.1 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ✓ Capital efficiency
- ✓ Share dilution — 23.4%
- ✗ Competitive moat — None
- ✓ Market size (TAM) — Large
Grade history
- 2026-08-18 — Promising (early) (from Mixed (early))
- 2026-06-10 — Mixed (early) (first graded)
Every grade change since FrontierLab began tracking this name — the receipts behind the current grade.
How have Early-stage-graded names performed?
The forward returns of all Early-stage-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 69% of Early-stage-graded names beat the S&P over 21 sessions (95% CI 51–82%, N=32). | Median excess vs the S&P was +3.9%. |
| ~3 months | building — 13 more sessions needed | |
| ~6 months | building — 76 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| Burning cash — operating margin is negative. | 35 | +7.4% |
| Heavy dilution (~23%/yr) — top-decile share issuers have historically underperformed. | sample still too small to report (need ≥ 8) | |
| Parabolic one-day spike (+13%) in the last month — extreme single-day moves tend to mean-revert. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
Fundamentals
| Market cap | $1.57B |
|---|---|
| Stage | Early |
| Share issuance (YoY) | 23.4% · heavy issuance |
| Moat | None |
| TAM | LARGE |
| P/E (trailing) | — |
| EPS (trailing) | $-0.80 |
| Burn multiple | — |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.75 |
| Accruals (%) | -5.4% |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-11 |
Momentum context — describes the past, not a signal
Low reached Mar 12, 2026 · high reached Jul 2, 2026 — by daily close.
| Price | $9.28 (as of 2026-08-20) |
|---|---|
| Last session move | — |
| % off 52-wk high | -23% |
| RSI (14) | 54 |
| Relative volume | 1.1× |
Risk flags
Insider activity (90 days)
| Cluster buyers | 1 |
|---|---|
| Sellers | 0 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 4 |
|---|---|
| Buy | 10 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
▼ Analyst view softening — net -1 buy rating, coverage 17→16 analysts over ~5 weeks (per aggregated analyst ratings)
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
AI take — daily, AI-generated
AI leans mixed
Promising grade but missing growth/margin data and negative GP/A (-0.01) leave too many unknowns.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Emerging Frontier names
← All Emerging Frontier names · Open ABSI in the interactive screener →
Data as of 2026-08-21 08:12 (end-of-day). How grades are computed →